Stocks making the biggest moves midday: Bed Bath & Beyond, Express, Snap, Rocket Lab and more

Stocks making the biggest moves midday: Bed Bath & Beyond, Express, Snap, Rocket Lab and more


Check out the companies making headlines in midday trading.

Bed Bath & Beyond — Shares of the beleaguered retailer tumbled 19.8% after it outlined a strategic plan that only confirmed investor fears that the company will struggle to turn around its business. Bed Bath also filed to sell an undisclosed amount of stock in the future.

Express — Express shares plunged more than 19% after reporting quarterly revenue of $464.4 million, compared to StreetAccount estimates of $479.6 million. The apparel retailer, wh aichlso cut its full-year guidance, cited challenging macroeconomic conditions.

Rocket Lab USA — Shares surged 8.2% after Cowen upgraded the company to outperform from market perform, saying that the shares have more than 50% upside. According to Cowen, Rocket Lab is the leader in the space launch market.

Snap — The social media company saw its shares rise 7% after it announced a restructuring plan that includes a 20% cut in its staff and a new chief operating officer. The changes come after Snap reported disappointing second-quarter earnings and said it would not provide guidance for its current quarter.

LSB Industries — Shares of U.S. nitrogen company LSB Industries gained 2.2% after UBS initiated coverage with a buy rating and a price target suggesting 30% upside. The company is set to benefit from the record spreads between low cost U.S. natural gas and high cost natural gas in Europe and Asia, according to UBS.

PayPal Holdings — PayPal shares advanced 2.7% after Bank of America upgraded the stock to a buy from neutral and hiked its price target on the payments firm. The bank said it expects activist Elliott Management to push for more cost cutting at PayPal, which could boost earnings going forward.

Seagate Technology Holdings — Shares of the data storage company slid more than 4% after Seagate cut its revenue guidance for the current quarter. The company said it expects revenue for the quarter ending Sept. 30 to be in a range of $2.0 billion to $2.2 billion, down from a range of $2.35 billion to $2.65 billion. The company cited weaker economic trends in parts of Asia.

CrowdStrike Holdings — The stock dropped 6.3% despite the cybersecurity firm reporting a beat on quarterly profit and revenue expectations, as well as issuing an upbeat forecast.

HP Inc. — Shares of the PC maker dropped more than 5% after the company reported a revenue miss amid a slowdown in spending on electronics. HP’s quarterly earnings matched analysts’ estimates, according to Refinitiv.

Chewy — Shares of the pets products retailer slid 7.4% after it issued weak current-quarter revenue guidance. Chewy reported a profit beat in its most recent quarter, but its revenue fell short of expectations. The company expects rising inflation will dent spending on pet products purchases.

PVH — The stock declined 9% after the owner of Tommy Hilfiger and Calvin Klein apparel brands cut its full-year outlook. At the same time, PVH said it’s reducing its global office workforce by 10%.

Baxter International — Shares climbed 2% after the health care company said its latest syringe infusion therapy was cleared by the U.S. Food and Drug Administration.

— CNBC’s Yun Li, Tanaya Macheel, Jesse Pound, Carmen Reinicke, Samantha Subin and Michelle Fox Theobald contributed reporting.



Source

Nike cuts 1,400 roles in second round of layoffs this year
Business

Nike cuts 1,400 roles in second round of layoffs this year

People walk past a Nike store in New York City, on April 2, 2025. Kylie Cooper | Reuters Nike announced a new round of layoffs on Thursday impacting approximately 1,400 roles across the organization, mostly concentrated in its technology department. In a note from COO Venkatesh Alagirisamy, the company said the layoffs were part of […]

Read More
Trump administration moves to reclassify cannabis in major shift that could expand research
Business

Trump administration moves to reclassify cannabis in major shift that could expand research

The Trump administration moved Thursday to reclassify cannabis under federal law, which could significantly expand scientific research into the drug’s medical uses. The change would not legalize the drug at the federal level, but shift cannabis from its current status as a Schedule I substance to Schedule III under the U.S. Drug Enforcement Administration’s controlled […]

Read More
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free
Business

Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free

U.S. President Donald Trump (C) speaks during an event on advancing health care affordability in the Oval Office of the White House on April 23, 2026 in Washington, DC. Alex Wong | Getty Images Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White […]

Read More